Written question asked by Lord Walton of Detchant (Crossbench) on Tuesday, 1 March 2016, in the House of Lords. It was due for an answer on Tuesday, 15 March 2016. It was answered by Lord Prior of Brampton (Conservative) on Monday, 14 March 2016 on behalf of the Department of Health.
Blood Diseases: Drugs
- Question
-
To ask Her Majesty’s Government whether appropriate treatment for patients with plasma disorders such as haemophilia and primary immunodeficiency, as provided for under the statutory scheme for branded medicines, will continue to be provided following the review of that scheme by the Department of Health.
- Answer
-
We are continuing to consider carefully all the consultation responses. It is important we get these changes right for patients, the National Health Service and industry. We want to look in particular at the impact on small and medium sized businesses, while securing the medicines patients need at a cost which the NHS can afford.
Secondary information
- Type
- Written question
- Reference
- HL6608
- Session
- 2015-16
- Subjects
- Drugs Blood diseases
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2016-07-05 19:41:13 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2015-16/HL6608
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2015-16/HL6608
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2015-16/HL6608